Journal of Gastroenterology

, Volume 43, Issue 5, pp 397–401

Reactivation of hepatitis B in a patient with Crohn’s disease treated using infliximab

Authors

  • Keisuke Ojiro
    • Department of Internal Medicine, School of MedicineKeio University
  • Makoto Naganuma
    • Department of Internal Medicine, School of MedicineKeio University
  • Hirotoshi Ebinuma
    • Department of Internal Medicine, School of MedicineKeio University
  • Hiroyoshi Kunimoto
    • Department of Internal Medicine, School of MedicineKeio University
  • Shinichiro Tada
    • Department of Internal Medicine, School of MedicineKeio University
  • Haruhiko Ogata
    • Department of Internal Medicine, School of MedicineKeio University
  • Yasushi Iwao
    • Department of Internal Medicine, School of MedicineKeio University
  • Hidetsugu Saito
    • Department of Internal Medicine, School of MedicineKeio University
  • Toshifumi Hibi
    • Department of Internal Medicine, School of MedicineKeio University
Case Report

DOI: 10.1007/s00535-008-2165-x

Cite this article as:
Ojiro, K., Naganuma, M., Ebinuma, H. et al. J Gastroenterol (2008) 43: 397. doi:10.1007/s00535-008-2165-x

Abstract

We encountered a case of reactivation of hepatitis B virus after administration of infliximab for Crohn’s disease. The use of infliximab was considered because the patient displayed abdominal symptoms and perianal lesions. Transaminases were normal, and hepatitis B virus (HBV) DNA was undetectable before treatment, so no antiviral treatment was used, and infliximab and low-dose 6-mercaptopurine were administered. This treatment was effective, but liver dysfunction and reactivation of HBV were observed after the fourth injection of infliximab. This is the first report of Crohn’s disease for which infliximab use was continued even after reactivation of HBV was observed. However, liver dysfunction was not improved by lamivudine. Antiviral treatment should be considered before administration of infliximab for patients with HBV.

Key words

Crohn’s diseaseinfliximabHBV
Download to read the full article text

Copyright information

© Springer Japan 2008